Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page
- Check6 days agoChange DetectedRecruitment status shows enrollment is closed, and new sections like How to Read a Study Record, Common Questions, How to Join a Study, and related topics have been added to guide users through the study information.SummaryDifference0.5%

- Check13 days agoChange DetectedThe footer now lists Revision: v3.5.5, replacing the previous revision, and several generic links/topics (Lung cancer, related topics, MedlinePlus Genetics) have been removed.SummaryDifference0.2%

- Check20 days agoChange DetectedAdded related topics and links for Lung cancer and MedlinePlus Genetics to the page's related information section, enhancing navigation to disease context and genetics resources.SummaryDifference0.1%

- Check27 days agoChange DetectedThe related topics section loses three items: Lung cancer, related topics:, and MedlinePlus Genetics, narrowing the list of disease tags and external resources associated with the study.SummaryDifference0.1%

- Check35 days agoChange DetectedThe page revision label was updated from v3.5.3 to v3.5.4, indicating a minor update to the study record. This does not appear to alter the study details themselves.SummaryDifference0.0%

- Check56 days agoChange DetectedThe page footer revision tag was updated from **v3.5.2** to **v3.5.3**, indicating a site/platform version update rather than a change to the study information.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.